Among the millions who have turned to GLP-1 medications like Ozempic as a cornerstone of modern diabetes care, roughly one in ten carry a quiet genetic difference that renders these drugs less effective — not through any failure of the medicine itself, but through a deeper biological resistance written into their DNA. Researchers at Stanford Medicine have traced this resistance to variants in genes governing a hormone-activating enzyme called PAM, offering the first molecular explanation for why some patients plateau where others thrive. The discovery opens a door toward precision medicine in
Rádio Pampa
· Jun 08, 2026
· health
· 3 min de lectura
High
Verificación: Verificado
Genetic variants explain why Ozempic fails for 10% of patients
◉
Health & Medicine
2821 artículos relacionados
Ozempic and GLP-1 drugs: how the weight-loss revolution works and what…
O GLOBO · 99% coincidencia
Eli Lilly's retatrutida shows 28% weight loss in trials, rivaling bari…
Poder360 · 90% coincidencia
GLP-1 drugs like Ozempic expand beyond weight loss into Alzheimer's, h…
Folha de S.Paulo · 90% coincidencia
Brazil's obesity guidelines shift focus from weight loss to disease ma…
Correio Braziliense · 90% coincidencia
Medical Expert Warns of Tirzepatide Risks, Emphasizes Need for Profess…
UNIPAR · 90% coincidencia
Cobertura Relacionada
REDE BRASIL DE TELEVISÃO · Aug 25
Endocrinologista explica por que emagrecer após os 40 exige abordagem integral
Endocrinologista explica que perda de peso após os 40 anos exige análise integrada de hormônios, sono e composição corpo…
Folha de S.Paulo · Aug 25 Zema critica vacinação obrigatória e nega golpe em entrevista ao Jornal NacionalCandidato presidencial Romeu Zema declarou-se contrário à vacinação obrigatória e prometeu anistia aos condenados pelos …
Super Rádio Tupi · Aug 25 Nova espécie de cão-urso do Mioceno revela predador pré-histórico desconhecidoPesquisadores identificaram uma nova espécie de cão-urso (anficionídeo) em fósseis de 16 milhões de anos, ampliando o co…
REDE BRASIL DE TELEVISÃO · Aug 25 Diagnóstico precoce de Alzheimer amplia possibilidades de tratamento, alerta FebrazCampanha Setembro Lilás 2026 alerta sobre importância do diagnóstico inicial de Alzheimer, com 84,3% de subdiagnóstico n…
Sesgo y Encuadre
No hay datos de análisis detallado para esta lente. Intenta volver a ejecutar las lentes desde el panel de administración.
Impacto Geopolítico
🌎
Stanford research identifies genetic variants in 10% of people causing GLP-1 resistance, with limited geopolitical implications but potential for precision medicine disparities between nations.
Escalation Risk
low
Confidence
MED
United States
European Union
Brazil
Global pharmaceutical markets
Advances in precision medicine genetics strengthen U.S. biotech leadership and Stanford's research influence. Unequal access to genetic testing and personalized treatments could widen healthcare disparities between developed and developing nations, affecting pharmaceutical market dynamics and healthcare policy globally.
Similar to the Human Genome Project era (2000s), where genetic discoveries concentrated research power in wealthy nations, potentially creating healthcare inequities between countries with advanced genomic infrastructure and those without.
Lente Económico
📈
Stanford researchers identify genetic variants in 10% of people causing GLP-1 resistance, explaining poor Ozempic efficacy in some diabetes patients and enabling precision medicine approaches.
Market Signal
mixed
Confidence
HIGH
Pharmaceutical/Biotechnology
Healthcare/Medical Services
Diagnostic Testing
Health Insurance
Patients with GLP-1 resistance variants may benefit from earlier identification enabling alternative treatments, reducing ineffective medication use and healthcare costs. However, genetic testing costs may increase upfront expenses for some consumers.
Potential regulatory push for genetic screening before GLP-1 prescription; insurance coverage decisions for pharmacogenomic testing; FDA guidance on precision medicine approaches for diabetes treatment; healthcare systems may adopt genetic profiling protocols.